Free tool
FAERS Monitor: Tobrex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050555 or its brand name (Tobrex, Tobramycin). Reports on generic versions are filed under their own applications.
Reports
12,764
Serious
10,320
81% of reports
Hospitalization
6,109
Death reported
1,284
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use795
- pneumonia776
- drug ineffective727
- acute kidney injury702
- dyspnoea696
- infective pulmonary exacerbation of cystic fibrosis611
- death488
- cough464
- condition aggravated457
- hospitalisation456
- infection453
- pyrexia436
- cystic fibrosis418
- fatigue412
- nausea387
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 85 |
| 2005 | 102 |
| 2006 | 83 |
| 2007 | 129 |
| 2008 | 110 |
| 2009 | 103 |
| 2010 | 117 |
| 2011 | 220 |
| 2012 | 211 |
| 2013 | 194 |
| 2014 | 294 |
| 2015 | 469 |
| 2016 | 538 |
| 2017 | 594 |
| 2018 | 1,083 |
| 2019 | 1,574 |
| 2020 | 1,391 |
| 2021 | 1,036 |
| 2022 | 972 |
| 2023 | 825 |
| 2024 | 1,046 |
| 2025 | 895 |
| 2026 | 692 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,395 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 611 | 208.2 | 191.8 | 111,725 |
| cystic fibrosisSignal | 418 | 134.5 | 121.9 | 51,092 |
| acute kidney injurySignal | 702 | 7.6 | 7.1 | 4,020 |
| infectionSignal | 453 | 5.2 | 4.7 | 1,525 |
| hospitalisationSignal | 456 | 4.9 | 4.5 | 1,419 |
| pneumoniaSignal | 776 | 4.0 | 3.7 | 1,734 |
| coughSignal | 464 | 2.7 | 2.5 | 513 |
| condition aggravatedSignal | 457 | 2.5 | 2.3 | 407 |
| pyrexiaSignal | 436 | 2.1 | 1.9 | 246 |
| dyspnoeaSignal | 696 | 2.0 | 1.9 | 371 |
| off label use | 795 | 1.5 | 1.4 | 136 |
| death | 488 | 0.9 | 0.9 | 2 |
| drug ineffective | 727 | 0.9 | 0.8 | 7 |
| fatigue | 412 | 0.9 | 0.8 | 8 |
| nausea | 387 | 0.8 | 0.7 | 19 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.